BACKGROUND: Emapticap pegol (NOX-E36) is a Spiegelmer® that specifically binds and inhibits the pro-inflammatory chemokine C-C motif-ligand 2 (CCL2) (also called monocyte-chemotactic protein 1). The objective of this exploratory study was to evaluate the safety and tolerability as well as the renoprotective and anti-diabetic potential of emapticap in type 2 diabetic patients with albuminuria. METHODS: A randomized, double-blind, placebo-controlled Phase IIa study was initiated in 75 albuminuric type 2 diabetics. Emapticap at 0.5 mg/kg and placebo were administered subcutaneously twice weekly for 12 weeks to 50 and 25 patients, respectively, followed by a treatment-free phase of 12 weeks. RESULTS: Twice weekly subcutaneous treatment with emapticap over 3 months was generally safe and well tolerated and reduced the urinary albumin/creatinine ratio (ACR) from baseline to Week 12 by 29% (P < 0.05); versus placebo a non-significant ACR reduction of 15% was observed (P = 0.221). The maximum difference, 26% (P = 0.064) between emapticap and placebo, was seen 8 weeks after discontinuation of treatment. At Week 12, the HbA1c changed by −0.31% in the emapticap versus +0.05% in the placebo group (P = 0.146). The maximum difference for HbA1c was observed 4 weeks after the last dose with −0.35% for emapticap versus +0.12% for placebo (P = 0.026). No relevant change in blood pressure or estimated glomerular filtration rate was seen between the treatment groups throughout the study. A post hoc analysis with exclusion of patients with major protocol violations, dual RAS blockade or haematuria increased the ACR difference between the two treatment arms to 32% at Week 12 (P = 0.014) and 39% at Week 20 (P = 0.010). CONCLUSIONS: Inhibition of the CCL2/CCL2 receptor axis with emapticap pegol was generally safe and well tolerated. Beneficial effects on ACR and HbA1c were observed in this exploratory study, which were maintained after cessation of treatment. Taken together, emapticap may have disease-modifying effects that warrant further investigation in adequately powered confirmatory studies.

Albert Szent Györgyi Health Center University of Szeged Szeged Hungary

Department of Nephrology and Hypertension Hannover Medical School Hannover Germany

Department of Nephrology Endocrinology and Metabolic Diseases Medical University of Silesia Katowice Poland

Institute for Clinical and Experimental Medicine Prague Czech Republic

NOXXON Pharma AG Berlin Germany

See more in PubMed

Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33: 73–77 PubMed PMC

Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8: 301–306 PubMed

Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol 2010; 30: 290–301 PubMed

Panee J. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. Cytokine 2012; 60: 1–12 PubMed PMC

Chow FY, Nikolic-Paterson DJ, Ma FY et al. . Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007; 50: 471–480 PubMed

Chow FY, Nikolic-Paterson DJ, Ozols E et al. . Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73–80 PubMed

Fufaa GD, Weil EJ, Nelson RG et al. . Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. Nephrol Dial Transplant 2015; 30: 599–606 PubMed PMC

Gnudi L. A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages? Nephrol Dial Transplant 2015; 30: 525–527 PubMed

Ninichuk V, Clauss S, Kulkarni O et al. . Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008; 172: 628–637 PubMed PMC

Sayyed SG, Ryu M, Kulkarni OP et al. . An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 2011; 80: 68–78 PubMed

Sullivan T, Miao Z, Dairaghi DJ et al. . CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 2013; 305: F1288–F1297 PubMed PMC

Seok SJ, Lee ES, Kim GT et al. . Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol Dial Transplant 2013; 28: 1700–1710 PubMed

Kang YS, Lee MH, Song HK et al. . CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010; 78: 883–894 PubMed

Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697–F701 PubMed

Giunti S, Barutta F, Perin PC et al. . Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol 2010; 8: 849–860 PubMed

Eulberg D, Jarosch F, Vonhoff S et al. . Spiegelmers for therapeutic applications—use of chiral principles in evolutionary selection techniques. In: Klussmann S. (ed). The Aptamer Handbook. Weinheim: Wiley-VCH, 2006,417–442

Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics. Drug Discov Today 2015; 20: 147–155 PubMed

Buter H, Navis G, Dullaart RP et al. . Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001; 16: 771–775 PubMed

de Zeeuw D, Coll B, Andress D et al. . The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1083–1093 PubMed PMC

Schjoedt KJ, Rossing K, Juhl TR et al. . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536–542 PubMed

Kulkarni O, Pawar RD, Purschke W et al. . Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18: 2350–2358 PubMed

de Zeeuw D, Bekker P, Henkel E et al. . The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 2015; 3: 687–696 PubMed

de Zeeuw D, Agarwal R, Amdahl M et al. . Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551 PubMed

Parving HH, Persson F, Lewis JB et al. . Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–2446 PubMed

Heerspink HJ, Kropelin TF, Hoekman J et al. . Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 2015; 26: 2055–2064 PubMed PMC

Ismail-Beigi F, Craven T, Banerji MA et al. . Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419–430 PubMed PMC

Levin SR, Coburn JW, Abraira C et al. . Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care 2000; 23: 1478–1485 PubMed

Goldfine AB, Fonseca V, Jablonski KA et al. . Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013; 159: 1–12 PubMed PMC

Susantitaphong P, Sewaralthahab K, Balk EM et al. . Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 2013; 26: 424–441 PubMed PMC

Mann JF, Schmieder RE, McQueen M et al. . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–553 PubMed

Clase CM, Gao P, Tobe SW et al. . Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011; 154: 310–318 PubMed

Fried LF, Emanuele N, Zhang JH et al. . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892–1903 PubMed

Mancia G, Fagard R, Narkiewicz K et al. . 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357 PubMed

Abstract. Kidney Int Suppl (2011) 2013; 3: 262

Chadban S, Howell M, Twigg S et al. . The CARI guidelines. Assessment of kidney function in type 2 diabetes. Nephrology (Carlton) 2010; 15(Suppl 1): S146–S161 PubMed